An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.
Fulltext:
58116.pdf
Embargo:
until further notice
Size:
174.1Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2004Source
European Journal of Cancer, 40, 9, (2004), pp. 1314-9ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Internal Medicine
Blood Transfusion and Transplantation Immunology
Orthopaedics
Journal title
European Journal of Cancer
Volume
vol. 40
Issue
iss. 9
Page start
p. 1314
Page end
p. 9
Subject
EBP 3: Effective Primary Care and Public Health; UMCN 1.5: Interventional oncology; UMCN 4.1: Microbial pathogenesis and host defenseAbstract
Oropharyngeal candidiasis is a frequent infection in cancer patients who receive cytotoxic drugs. In this study, the efficacy, safety and tolerance of fluconazole and itraconazole were compared in non-neutropenic cancer patients with oropharyngeal candidiasis. Of 279 patients who were randomised between the two treatment groups, 252 patients were considered to be eligible (126 in each group). The clinical cure rate was 74% for fluconazole and 62% for itraconazole (P=0.04, 95% Confidence Interval (CI): 0.5-23.3%). The mycological cure rate was 80% for fluconazole and 68% for itraconazole (P=0.03, 95% CI: 1.2-22.6%). The safety and tolerance profile of both drugs were comparable. This study has shown that in patients with cancer and oropharyngeal candidiasis, fluconazole has a significantly better clinical and mycological cure rate compared with itraconazole.
This item appears in the following Collection(s)
- Academic publications [238426]
- Electronic publications [122508]
- Faculty of Medical Sciences [90358]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.